Mirtazapin Ratiopharm (Mirtazapine)

Mirtazapin Ratiopharm (mirtazapine) is used within the antidepressant therapeutic class to manage depressive conditions.

• Major depressive disorder: reduces depressive symptoms and improves overall mood.
• Depressive episodes in bipolar disorder: helps alleviate the depressive phase when used under specialist supervision.
• Treatment‑resistant depression: may be considered as an alternative when first‑line agents are ineffective.

• Mirtazapine acts as an antagonist at central presynaptic α2‑adrenergic receptors, thereby increasing noradrenaline release, and blocks 5‑HT2 and 5‑HT3 serotonin receptors as well as H1 histamine receptors. This combined activity enhances serotonergic and noradrenergic neurotransmission while producing sedative effects, contributing to its antidepressant action.

Mirtazapin Ratiopharm may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects

• Sedation or drowsiness
• Increased appetite leading to weight gain
• Dry mouth
• Constipation
• Dizziness
• Orthostatic hypotension

Serious or Rare Side Effects

• Agranulocytosis or severe neutropenia
• Stevens‑Johnson syndrome or toxic epidermal necrolysis
• Suicidal thoughts, especially early in treatment
• Seizures
• Hepatic dysfunction or jaundice

Before initiating therapy, clinicians should consider several safety aspects.

• Monitor weight: significant weight gain may occur.
• Assess for suicidal ideation: especially during the first weeks of treatment.
• Avoid abrupt discontinuation: tapering is recommended to reduce withdrawal symptoms.
• Caution in hepatic impairment: dose adjustment may be required.
• Pregnancy and lactation: discuss risks and benefits with the prescriber.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapin Ratiopharm can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome.
• Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels.
• CYP1A2 inducers (e.g., carbamazepine, smoking): may reduce efficacy.
• Antihistamines: additive anticholinergic effects.